what is the most performance mid cap stock between february 22 2018 and march 8 2018

Apellis Pharmaceuticals (APLS) had the highest return between February 22, 2018 and March 8, 2018 by a mid-cap US stock, returning 49.9%.

ASSET DATE % RETURN
Apellis Pharmaceuticals (APLS)
2/22/2018 - 3/8/2018
49.87%
Enphase Energy (ENPH)
2/22/2018 - 3/8/2018
44.11%
Crispr Therapeutics (CRSP)
2/22/2018 - 3/8/2018
27.86%
CNX Resources (CNX)
2/22/2018 - 3/8/2018
24.48%
Verona Pharma PLC ADR (VRNA)
2/22/2018 - 3/8/2018
22.87%
United States Cellular (USM)
2/22/2018 - 3/8/2018
22.58%
Etsy (ETSY)
2/22/2018 - 3/8/2018
22.41%
Dillards (DDS)
2/22/2018 - 3/8/2018
21.82%
Pegasystems (PEGA)
2/22/2018 - 3/8/2018
20.46%
TG Therapeutics (TGTX)
2/22/2018 - 3/8/2018
17.5%
Chart Industries (GTLS)
2/22/2018 - 3/8/2018
17.11%
Xenon Pharmaceuticals (XENE)
2/22/2018 - 3/8/2018
17.01%
Fabrinet (FN)
2/22/2018 - 3/8/2018
16.87%
Planet Fitness (PLNT)
2/22/2018 - 3/8/2018
16.81%
Sarepta Therapeutics (SRPT)
2/22/2018 - 3/8/2018
16.7%
Integer (ITGR)
2/22/2018 - 3/8/2018
16.36%
ADMA Biologics (ADMA)
2/22/2018 - 3/8/2018
15.58%
Soleno Therapeutics (SLNO)
2/22/2018 - 3/8/2018
15.52%
Range Resources (RRC)
2/22/2018 - 3/8/2018
15.31%
Krystal Biotech (KRYS)
2/22/2018 - 3/8/2018
15.09%
Telephone and Data Systems (TDS)
2/22/2018 - 3/8/2018
15.02%
Korn Ferry (KFY)
2/22/2018 - 3/8/2018
14.96%
Impinj (PI)
2/22/2018 - 3/8/2018
14.95%
TriNet (TNET)
2/22/2018 - 3/8/2018
14.45%
Teradata (TDC)
2/22/2018 - 3/8/2018
14.16%
Mid-cap stocks are treated as having a market cap between $2B and $10B.